Ghrelin - Asubio

Drug Profile

Ghrelin - Asubio

Alternative Names: SUN 11031

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asubio Pharma
  • Class Peptide hormones
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Anorexia nervosa; Cachexia

Most Recent Events

  • 31 May 2015 No recent reports of development identified - Phase-II for Cachexia in Europe and USA (SC)
  • 31 May 2015 No recent reports of development identified - Phase-III for Anorexia nervosa in Japan (SC)
  • 15 Feb 2011 Ghrelin - Asubio is available for licensing as of 15 Feb 2011. http://www.asubio.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top